ID
11710
Description
Through last couple of years the number of patients treated for acute coronary event without persistent ST segment elevation in ECG has been growing. This is probably an effect of improving diagnostics of myocardial infraction without persistent ST segment elevation in ECG, due to routine Troponin serum level evaluation and better primary prevention. This fact makes the search for the optimal treatment for patients with acute coronary event without persistent ST segment elevation in ECG, including both patients intended for pharmacological and invasive treatment percutaneous coronary intervention (PCI) or coronary artery byppass grafting (CABG). Patients undergoing invasive treatment for acute coronary event, have higher risk rate, than those with stabile angina pectoris. The authors of this study want to evaluate, whether the proportional use of platelet GP IIb/IIIa receptor antagonist - eptifibatide in patients undergoing CABG results in improvement of short-, and long time results in those patients. Eptifibatide ( Integrilin) a cyclic heptapeptide antagonist of the GP IIb/IIIa integrin receptor, is an intravenous antagonist with rapid onset and short half-life. https://clinicaltrials.gov/ct2/show/NCT01863134
Link
https://clinicaltrials.gov/ct2/show/NCT01863134
Keywords
Versions (1)
- 7/28/15 7/28/15 -
Uploaded on
July 28, 2015
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Eptifibatide Acute Coronary Syndrome NCT01863134
Eligibility criteria
- StudyEvent: ODM
Description
Exclusion Criteria
Description
Women who are pregnant or nursing.
Data type
boolean
Alias
- UMLS CUI-1
- C0549206
Description
Angina lasting longer than 24h
Data type
boolean
Alias
- UMLS CUI-1
- C0002962
Description
ST segment elevation - Pardy wave
Data type
boolean
Alias
- UMLS CUI-1
- C0520886
Description
age over 75 years
Data type
boolean
Alias
- UMLS CUI-1
- C0001779
Description
history of revascularization procedure during last 6 months (PTCA, CABG)
Data type
boolean
Alias
- UMLS CUI-1
- C0027056
Description
chronic heart failure (NYHA III or IV) during pre-hospitalization period
Data type
boolean
Alias
- UMLS CUI-1
- C0018802
Description
History of bleeding from gastrointestinal tract system during last 30 days
Data type
boolean
Alias
- UMLS CUI-1
- C0017181
Description
History of bleeding from genitourinary system during last 30 days
Data type
boolean
Alias
- UMLS CUI-1
- C0919591
Description
history of intracranial lesions or stroke
Data type
boolean
Alias
- UMLS CUI-1
- C0559159
Description
history of major surgery during last 6 weeks
Data type
boolean
Alias
- UMLS CUI-1
- C0679637
Description
history of trauma during last 6 weeks
Data type
boolean
Alias
- UMLS CUI-1
- C3714660
Description
history of hemorrhagic diathesis
Data type
boolean
Alias
- UMLS CUI-1
- C3251812
Description
thrombocytopenia < 100 000/mm3
Data type
boolean
Alias
- UMLS CUI-1
- C0040034
Description
anticoagulant therapy with INR>2,0
Data type
boolean
Alias
- UMLS CUI-1
- C0003280
Description
significant hepatic failure
Data type
boolean
Alias
- UMLS CUI-1
- C0085605
Description
significant renal failure with serum creatinine>2,0 mg%
Data type
boolean
Alias
- UMLS CUI-1
- C0035078
Description
elevated blood pressure: SBP>200mmHg and/or DBP>110mmHg despite the antihypertensive treatment
Data type
boolean
Alias
- UMLS CUI-1
- C0020538
Description
allergy to drugs or any therapeutic agent
Data type
boolean
Alias
- UMLS CUI-1
- C0013182
Similar models
Eligibility criteria
- StudyEvent: ODM